论文部分内容阅读
目的观察大补阴丸联合促性腺激素释放激素拮抗剂(GnRHa)治疗女童中枢性性早熟的临床疗效。方法将83例中枢性性早熟女性患儿随机分为2组,对照组38例采用GnRHa(达菲林)药物治疗,治疗组45例在对照组治疗方法的基础上采用大补阴丸治疗,1年为1个疗程,对比治疗前、后2组患儿的子宫、卵巢大小,骨龄指数及性激素变化水平,同时记录患儿的身高增长速率及治疗期间不良反应发生情况。结果 2组治疗后子宫、卵巢大小,骨龄指数及性激素水平均显著下降,与治疗前比较差异有统计意义(P<0.05或P<0.01),且治疗组下降幅度优于对照组(P<0.01);对照组总有效率为71.05%,治疗组为88.89%,2组总有效率经统计学分析,差异有统计意义(P<0.05);对照组生长速率为(7.15±1.75)cm/年,治疗组为(4.96±1.34)cm/年,经统计学分析,差异有高度统计意义(P<0.01);2组患儿治疗期间未见不良反应发生。结论大补阴丸联合GnRHa治疗女童中枢性性早熟疗效显著,不良反应少,值得推广应用。
Objective To observe the clinical efficacy of Dabuyin Pill combined with gonadotropin-releasing hormone antagonist (GnRHa) in the treatment of central precocious puberty in girls. Methods 83 cases of precocious puberty female children were randomly divided into two groups, the control group of 38 patients with GnRHa (Tamiflu) drug treatment, the treatment group of 45 patients in the control group based on the treatment of Dabuyin Pill, 1 Year for a course of treatment, before and after treatment compared the uterus, ovarian size, bone age index and sex hormone levels in two groups of children, while recording the rate of height growth in children with adverse reactions during treatment. Results After treatment, the uterus, ovarian size, bone age index and sex hormone levels were significantly decreased in both groups (P <0.05 or P <0.01), and the reduction rate in the treatment group was better than that in the control group (P <0.01) ). The total effective rate was 71.05% in the control group and 88.89% in the treatment group. The total effective rate in the two groups was statistically analyzed (P <0.05), and the growth rate in the control group was (7.15 ± 1.75) cm / year , The treatment group was (4.96 ± 1.34) cm / year, and the difference was statistically significant (P <0.01). No adverse reactions occurred in the two groups during treatment. Conclusion Dabuyin Pills combined with GnRHa treatment of central precocious puberty girls significant effect, less adverse reactions, it is worth promoting the application.